Abstract:Background Bone erosions are a key feature of rheumatoid arthritis (RA) reflecting both disease severity and disease progression. Recent studies using HR-pQCT demonstrated impairment in the bone microstructure of the metacarpophalangeal (MCP) joints of ACPAs-positive healthy individuals despite no signs of arthritis. In patients with established RA, ACPAs and rheumatoid factor (RF) showed an additive effect on erosion number and erosion size. Furthermore, RF influences erosion size only in ACPAs-positive but not in ACPAs-negative patients. Objectives To determine the effect of high titre of anticitrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) on the number and size of bone erosions in patients with early rheumatoid arthritis (ERA) by high-resolution peripheral quantitative computed tomography (HR-pQCT) at baseline and whether these antibodies are associated with the progression of erosion after one year of follow-up. Methods In the cross-sectional study, HR-pQCT of the second metacarpophalangeal joint (MCP2) was performed in 124 patients with ERA at baseline, images were analysable in 117 patients. Erosions were visualized in 72 patients and parameters of bone erosions were assessed. In the prospective study, 63 ERA patients who had completed one year of follow-up with repeat HR-pQCT scan were also analysed. The number and volume of the erosions as well as bone mineral density (BMD) surrounding erosion were quantified. Data on demographic and disease-specific parameters including ESR, CRP, DAS 28, ACPAs and RF levels and treatment were recorded. Results At baseline, 90/117 patients were both ACPAs and RF positive (ACPAs+/RF+ group), 7/117 were only RF (RF+), 13/117 were only ACPAs (ACPAs+) and 7/117 were antibody negative (non-ACPAs+/RF+ group, n=27). Erosion depth and volume were increased in the ACPAs+/RF+ group compared with the non-ACPAs+/RF+ group (both P<0.05) (Table 1). Independent explanatory variables associated with a larger erosion volume included RF>16U (P=0.012), older age (P=0.003) and a higher damage joint count (P=0.028). Images from 63 patients who completed 12 months follow-up were analysed. Erosion volume were significantly lower in patients who achieved simplified disease activity score (SDAI) remission at 12 months compared to those who did not (P=0.045). Linear regression analysis indicated that independent predictors for an increase in erosion volume included RF>16U (P=0.032) and a higher damage joint count (P=0.009) at baseline and failure to achieve SDAI remission at 1 year (P=0. 043). Conclusions ACPAs and RF show an additive effect on erosion volume in ERA patients. Higher RF titre was associated with larger erosion volume at baseline and predicted progression of erosion volume after adjusting for baseline parameters and treatment response. Disclosure of Interest None declared

Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

Impact of Treat-to-Target Therapy on Bone Mineral Density Loss in Patients with Rheumatoid Arthritis: A Prospective Cohort Study

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

The clinical assessment of changes in bone density in Rheumatoid Arthritis patients': Role of DEXA scan and bone turnover biomarkers

Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis

Professional antigen‐presenting Tbet+CD11c+ B cells correlate with bone destruction in untreated rheumatoid arthritis

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion

Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis

Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a period of 24 years: experiences of a single centre

Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT

Plasma Sclerostin Levels in Rheumatoid Arthritis Women on TNF-α Inhibitor Therapy

Decreased Quantity and Quality of the Periarticular and Nonperiarticular Bone in Patients With Rheumatoid Arthritis: A Cross‐Sectional HR‐pQCT Study

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis

A Clinical Evaluation of the Role of Autoimmunity in the Relation Between Erosions and Bone Mineral Density in Rheumatoid Arthritis

AB0424 the Effect of High Level of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor on Bone Erosions in Patients with Early Rheumatoid Arthritis– a Cross-Sectional and Longitudinal Analysis

Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study

The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis—A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study

Red Cell Distribution Width and Absolute Lymphocyte Count Associate With Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis

Muscle Deficits in Rheumatoid Arthritis Contribute to Inferior Cortical Bone Structure and Trabecular Bone Mineral Density.

T Helper 17 and T Helper 1 Cells Are Increased but Regulatory T Cells Are Decreased in Subchondral Bone Marrow Microenvironment of Patients with Rheumatoid Arthritis.